Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decibel Therapeutics, Inc.DBTX · Entity 109458 | Director | February 11, 2021 | February 16, 2021 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | Director · Vice Chairman | February 12, 2009 | February 18, 2009 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
| PRUDENTIAL FINANCIAL INCPRU · Entity 148 | Director | September 10, 2026 | September 14, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
| SHERWIN WILLIAMS COSHW · Entity 2948 | Director | April 04, 2025 | April 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decibel Therapeutics, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2031-02-10 | Direct | 20,000 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 20,000 · Balance 20,000 F1: The option was granted on February 11, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on February 11, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service.
JOHNSON & JOHNSON
Report date February 12, 2009 · Filed February 18, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 55,711 |
Ending reported balance
After 2009-02-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2009-02-13 · Exercise / conversion · Acquired 17,141 · Balance 61,942 Row 2 · 2009-02-13 · Tax withholding · Disposed 6,231 · Balance 55,711 |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,165 |
Reported balance
After 2009-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2009-02-12 · Grant · Acquired 3,949 · Balance 16,165 F3: The Phantom Stock converts into Common Stock on a one-for-one basis. F4: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2009-02-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-02-13 · Exercise / conversion · Disposed 17,141 · Balance 0 F5: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 13, 2006, represents a contingent right to receive one share of Company Common Stock. F6: Not applicable. |
| CommonSEC Table I · non-derivative | IndirectJohnson & Johnson Stock Fund under the 401(k) Savings Plan | 16 |
Reported balance
Holding disclosure · report date 2009-02-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 16 F1: Shares held in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009). |
| CommonSEC Table I · non-derivative | IndirectESOP under the 401(k) Savings Plan | 162 |
Reported balance
Holding disclosure · report date 2009-02-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 162 F2: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009). |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009).
F2: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009).
F3: The Phantom Stock converts into Common Stock on a one-for-one basis.
F4: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement.
F5: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 13, 2006, represents a contingent right to receive one share of Company Common Stock.
F6: Not applicable.
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,567 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
PRUDENTIAL FINANCIAL INC
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Notional Shares - MandatorySEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,840 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 161 · Balance 13,840 F1: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors. F2: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. |
| Notional Shares - OptionalSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,248 |
Reported balance
After 2026-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-10 · Grant · Acquired 49 · Balance 4,248 F3: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors. F4: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. |
| 2026 Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,798 |
Reported balance
After 2026-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-10 · Grant · Acquired 21 · Balance 1,798 F5: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F6: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors.
F2: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2.
F3: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors.
F4: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors.
F5: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock.
F6: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2027.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,219 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 5,219 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
SHERWIN WILLIAMS CO
Report date April 04, 2025 · Filed April 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDeferred Fee Plan | 2,573.38 |
Reported balance
After 2025-04-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-04-04 · Grant · Acquired 4.11 · Balance 2,573.38 F1: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company. F2: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units credited to the Reporting Person's account. F3: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan. |
| Common StockSEC Table I · non-derivative | Direct | 12,386 |
Reported balance
Holding disclosure · report date 2025-04-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,386 F4: These securities consist of 1,150 restricted stock units ("RSUs") and 11,236 shares of common stock. Each RSU represents the Reporting Person's right to receive one share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of deferred stock units acquired by the Reporting Person, in an exempt transaction, pursuant to the 2005 Director Deferred Fee Plan ("Deferred Fee Plan"). Each deferred stock unit is the economic equivalent of one share of common stock. The deferred stock units become payable solely in stock, generally following the Reporting Person's separation from service as a Director of the Company.
F2: Represents the weighted average share price on the transaction date used to determine the number of deferred stock units credited to the Reporting Person's account.
F3: These securities consist of deferred stock units, held pursuant to the Deferred Fee Plan, and include deferred stock units acquired pursuant to the dividend reinvestment feature of such Plan.
F4: These securities consist of 1,150 restricted stock units ("RSUs") and 11,236 shares of common stock. Each RSU represents the Reporting Person's right to receive one share of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2021 Filed Sep 20, 2021 20:50 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Optional · Derivative | 36 | $103.61 Strike: $0.00 | $3,729.96 |
DisclosureSEC source: 0001127602-21-025617 · form4.xml · derivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,316 Underlying: Common Stock · 36 shares Expires not disclosed F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 20:50 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Mandatory · Derivative | 118 | $103.61 Strike: $0.00 | $12,225.98 |
DisclosureSEC source: 0001127602-21-025617 · form4.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,804 Underlying: Common Stock · 118 shares Expires not disclosed F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors. F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · derivative · entry 13 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 112 | $672.27 | $75,294.24 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 12 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681 F10 · price: Represents volume-weighted average price of sales of 112 shares of Company stock on August 27, 2021 at prices ranging from $672.27 to $672.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,737 | $671.49 | $1,166,378.13 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 11 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,793 F9 · price: Represents volume-weighted average price of sales of 1,737 shares of Company stock on August 27, 2021 at prices ranging from $671.00 to $671.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,447 | $670.48 | $2,311,144.56 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 10 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,530 F8 · price: Represents volume-weighted average price of sales of 3,447 shares of Company stock on August 27, 2021 at prices ranging from $670.01 to $670.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,235 | $669.59 | $1,496,533.65 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 9 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,977 F7 · price: Represents volume-weighted average price of sales of 2,235 shares of Company stock on August 27, 2021 at prices ranging from $669.17 to $669.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 603 | $668.33 | $403,002.99 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 8 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,212 F6 · price: Represents volume-weighted average price of sales of 603 shares of Company stock on August 27, 2021 at prices ranging from $668.04 to $668.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,150 | $667.37 | $1,434,845.50 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 7 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,815 F5 · price: Represents volume-weighted average price of sales of 2,150 shares of Company stock on August 27, 2021 at prices ranging from $667.01 to $667.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,118 | $666.70 | $745,370.60 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 6 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,965 F4 · price: Represents volume-weighted average price of sales of 1,118 shares of Company stock on August 27, 2021 at prices ranging from $666.39 to $666.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 538 | $665.33 | $357,947.54 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 5 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,083 F3 · price: Represents volume-weighted average price of sales of 538 shares of Company stock on August 27, 2021 at prices ranging from $665.07 to $665.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 700 | $664.42 | $465,094.00 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 4 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,621 F2 · price: Represents volume-weighted average price of sales of 700 shares of Company stock on August 27, 2021 at prices ranging from $664.00 to $664.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,260 | $663.51 | $1,499,532.60 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,321 F1 · price: Represents volume-weighted average price of sales of 2,260 shares of Company stock on August 27, 2021 at prices ranging from $663.11 to $663.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2021 at each separate price. Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $662.62 | $66,262.00 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,581 Read SEC document |
| August 27, 2021 Filed Aug 31, 2021 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 15,000 | $57.11 | $856,650.00 |
DisclosureSEC source: 0001708138-21-000068 · edgardoc.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 17:53 UTC | SHERWIN WILLIAMS CO SHW · Entity 2948 | GrantCommon Stock | 28.41 | $274.96 | $7,811.61 |
DisclosureSEC source: 0001209191-21-045765 · doc4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Plan Disclosed balance after: 2,071.9 F1 · kind: Represents the number of phantom stock units acquired by the reporting person (in an exempt transaction) under the 2005 Director Deferred Fee Plan. Each phantom stock unit is the economic equivalent of one share of common stock. The phantom stock units become payable solely in stock generally upon the reporting person's retirement. F2 · balance_after: Phantom stock units listed are held pursuant to the 2005 Director Deferred Fee Plan, which includes phantom stock units acquired pursuant to the dividend reinvestment feature of such plan. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:34 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Grant2021 Restricted Stock Units · Derivative | 16 | $100.64 | $1,610.24 |
DisclosureSEC source: 0001127602-21-020417 · form4.xml · derivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,446 Underlying: Common Stock · 16 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 11, 2022. F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 11, 2022. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:34 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Optional · Derivative | 37 | $100.64 Strike: $0.00 | $3,723.68 |
DisclosureSEC source: 0001127602-21-020417 · form4.xml · derivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Underlying: Common Stock · 37 shares Expires not disclosed F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:34 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Mandatory · Derivative | 120 | $100.64 Strike: $0.00 | $12,076.80 |
DisclosureSEC source: 0001127602-21-020417 · form4.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,685 Underlying: Common Stock · 120 shares Expires not disclosed F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors. F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:56 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Grant2021 Restricted Stock Units · Derivative | 1,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016614 · form4.xml · derivative · entry 4 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 1,429 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F3 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 11, 2022. F3 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 11, 2022. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:56 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Exercise / conversion2020 Restricted Stock Units · Derivative | 2,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016614 · form4.xml · derivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F2 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. F2 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:56 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Disposition to issuerCommon Stock | 2,933 | $104.91 | $307,701.03 |
DisclosureSEC source: 0001127602-21-016614 · form4.xml · nonDerivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,583 Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:56 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Exercise / conversionCommon Stock | 2,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016614 · form4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:07 UTC | SHERWIN WILLIAMS CO SHW · Entity 2948 | GrantCommon Stock | 30.84 | $253.36 | $7,813.62 |
DisclosureSEC source: 0001209191-21-025905 · doc4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Plan Disclosed balance after: 2,039.53 F1 · kind: Represents the number of phantom stock units acquired by the reporting person (in an exempt transaction) under the 2005 Director Deferred Fee Plan. Each phantom stock unit is the economic equivalent of one share of common stock. The phantom stock units become payable solely in stock generally upon the reporting person's retirement. F2 · balance_after: Phantom stock units listed are held pursuant to the 2005 Director Deferred Fee Plan, which includes phantom stock units acquired pursuant to the dividend reinvestment feature of such plan. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 23:42 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Grant2020 Restricted Stock Units · Derivative | 36 | $92.41 | $3,326.76 |
DisclosureSEC source: 0001127602-21-010666 · form4.xml · derivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,933 Underlying: Common Stock · 36 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 23:42 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Optional · Derivative | 39 | $92.41 Strike: $0.00 | $3,603.99 |
DisclosureSEC source: 0001127602-21-010666 · form4.xml · derivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,242 Underlying: Common Stock · 39 shares Expires not disclosed F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 23:42 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Mandatory · Derivative | 129 | $92.41 Strike: $0.00 | $11,920.89 |
DisclosureSEC source: 0001127602-21-010666 · form4.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,564 Underlying: Common Stock · 129 shares Expires not disclosed F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors. F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:49 UTC | SHERWIN WILLIAMS CO SHW · Entity 2948 | GrantCommon Stock | 221 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012020 · doc4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,345 F1 · kind: Grant of restricted stock units under The Sherwin-Williams Company 2006 Stock Plan for Nonemployee Directors. F2 · balance_after: Of shares listed, 541 are restricted stock units. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:37 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006697 · doc4.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The option was granted on February 11, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:13 UTC | SHERWIN WILLIAMS CO SHW · Entity 2948 | GrantCommon Stock | 10.73 | $727.84 | $7,809.72 |
DisclosureSEC source: 0001209191-21-003178 · doc4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Plan Disclosed balance after: 668 F1 · kind: Represents the number of phantom stock units acquired by the reporting person (in an exempt transaction) under the 2005 Director Deferred Fee Plan. Each phantom stock unit is the economic equivalent of one share of common stock. The phantom stock units become payable solely in stock generally upon the reporting person's retirement. F2 · balance_after: Phantom stock units listed are held pursuant to the 2005 Director Deferred Fee Plan, which includes phantom stock units acquired pursuant to the dividend reinvestment feature of such plan. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001708138-21-000008 · edgardoc.xml · derivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000008 · edgardoc.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 23:08 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Grant2020 Restricted Stock Units · Derivative | 40 | $77.66 | $3,106.40 |
DisclosureSEC source: 0001127602-20-032055 · form4.xml · derivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897 Underlying: Common Stock · 40 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 23:08 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Optional · Derivative | 44 | $77.66 Strike: $0.00 | $3,417.04 |
DisclosureSEC source: 0001127602-20-032055 · form4.xml · derivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,202 Underlying: Common Stock · 44 shares Expires not disclosed F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 23:08 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Mandatory · Derivative | 145 | $77.66 Strike: $0.00 | $11,260.70 |
DisclosureSEC source: 0001127602-20-032055 · form4.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,434 Underlying: Common Stock · 145 shares Expires not disclosed F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors. F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 18:05 UTC | SHERWIN WILLIAMS CO SHW · Entity 2948 | GrantCommon Stock | 11.34 | $688.84 | $7,811.45 |
DisclosureSEC source: 0001209191-20-053978 · doc4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Plan Disclosed balance after: 656.02 F1 · kind: Represents the number of phantom stock units acquired by the reporting person (in an exempt transaction) under the 2005 Director Deferred Fee Plan. Each phantom stock unit is the economic equivalent of one share of common stock. The phantom stock units become payable solely in stock generally upon the reporting person's retirement. F2 · balance_after: Phantom stock units listed are held pursuant to the 2005 Director Deferred Fee Plan, which includes phantom stock units acquired pursuant to the dividend reinvestment feature of such plan. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 20:39 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | Grant2020 Restricted Stock Units · Derivative | 45 | $68.59 | $3,086.55 |
DisclosureSEC source: 0001127602-20-025493 · form4.xml · derivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 45 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of PRU common stock. F6 · derivative.exercise_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. F6 · derivative.expiration_date: The restricted stock units vest the earlier of the annual meeting or in one year on May 12, 2021. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 20:39 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Optional · Derivative | 49 | $68.59 Strike: $0.00 | $3,360.91 |
DisclosureSEC source: 0001127602-20-025493 · form4.xml · derivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 Underlying: Common Stock · 49 shares Expires not disclosed F3 · derivative.exercise_price: Each notional share - optional represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock or the cash value thereof under the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.exercise_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. F4 · derivative.expiration_date: Such shares are payable in common stock or cash, at the election of the reporting person, with payment to begin, at the election of the reporting person provided that such date shall be at least two (2) years after the end of the plan year with respect to which such elective deferrals relate. The reporting person may transfer her investment in the notional shares - optional to an alternative investment account, subject to the terms of the Issuer's deferred compensation plan for non-employee directors. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 20:39 UTC | PRUDENTIAL FINANCIAL INC PRU · Entity 148 | GrantNotional Shares - Mandatory · Derivative | 162 | $68.59 Strike: $0.00 | $11,111.58 |
DisclosureSEC source: 0001127602-20-025493 · form4.xml · derivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,289 Underlying: Common Stock · 162 shares Expires not disclosed F1 · derivative.exercise_price: Each notional share - mandatory represents a deferred stock unit and entitles the holder thereof with the right to receive one share of Issuer common stock under the Issuer's deferred compensation plan for non-employee directors. F2 · derivative.exercise_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. F2 · derivative.expiration_date: Such shares are issuable, at the election of the reporting person, to begin on either (i) a date prior to the reporting person's retirement date, provided that such date is no earlier than the January 1 in the year following the plan period during which such fees would otherwise have been payable to the reporting person, (ii) within 90 days following the reporting person's retirement date, or (iii) such later date as selected by the reporting person, provided however, that payment must commence in the year the reporting person attains age 70 1/2. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · derivative · entry 10 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · derivative · entry 9 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 693 | $603.20 | $418,017.60 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 8 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433 F6 · price: Represents volume-weighted average price of sales of 693 shares of Company stock on August 28, 2020 at prices ranging from $603.00 to $603.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2020 at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,899 | $602.39 | $7,770,228.61 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 7 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,126 F5 · price: Represents volume-weighted average price of sales of 12,899 shares of Company stock on August 28, 2020 at prices ranging from $602.00 to $602.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2020 at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8,011 | $601.53 | $4,818,856.83 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 6 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,025 F4 · price: Represents volume-weighted average price of sales of 8,011 shares of Company stock on August 28, 2020 at prices ranging from $601.00 to $601.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2020 at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12,490 | $600.44 | $7,499,495.60 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 5 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,036 F3 · price: Represents volume-weighted average price of sales of 12,490 shares of Company stock on August 28, 2020 at prices ranging from $600.00 to $600.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2020 at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,730 | $599.67 | $3,436,109.10 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 4 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,526 F2 · price: Represents volume-weighted average price of sales of 5,730 shares of Company stock on August 28, 2020 at prices ranging from $599.00 to $599.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2020 at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 177 | $598.91 | $106,007.07 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 3 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,256 F1 · price: Represents volume-weighted average price of sales of 177 shares of Company stock on August 28, 2020 at prices ranging from $598.90 to $598.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 28, 2020 at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,000 | $25.45 | $636,250.00 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 2 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:35 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 15,000 | $33.42 | $501,300.00 |
DisclosureSEC source: 0001237899-20-000037 · edgardoc.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:17 UTC | SHERWIN WILLIAMS CO SHW · Entity 2948 | GrantCommon Stock | 13.28 | $588.25 | $7,811.96 |
DisclosureSEC source: 0001209191-20-041749 · doc4.xml · nonDerivative · entry 1 POON CHRISTINE A · CIK 0001189014 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Plan Disclosed balance after: 643.45 F1 · kind: Represents the number of phantom stock units acquired by the reporting person (in an exempt transaction) under the 2005 Director Deferred Fee Plan. Each phantom stock unit is the economic equivalent of one share of common stock. The phantom stock units become payable solely in stock generally upon the reporting person's retirement. F2 · balance_after: Phantom stock units listed are held pursuant to the 2005 Director Deferred Fee Plan, which includes phantom stock units acquired pursuant to the dividend reinvestment feature of such plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.